Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

Oct 23, 2019

BioMarin Announces Third Quarter 2019 Financial Results

- The Company Achieved Record Total Revenues of $461.1 million; Increased 18% Year Over Year

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 % Change 2019 2018 % Change Total...
Oct 9, 2019

BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday,...
Oct 7, 2019
BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives...
- Photos 1
Oct 1, 2019

BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the...
Sep 26, 2019

BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU

BMN 307 Represents a Potential 3rd PKU Treatment Option in BioMarin's PKU Franchise

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a Clinical Trial Application...